Madrid, 9 June 2026.

• Within the framework of the VII National Biosimilars Conference, the president of BioSim highlighted the Pharmaceutical Industry Strategy of the Ministry of Health as a roadmap to move towards a more competitive, resilient and patient-oriented healthcare ecosystem.
• BioSim has put forward a proposal aimed at implementing a Biosimilars Plan in Spain that seeks a rapid adoption of these drugs.

During the opening of the VII National Biosimilars Conference, held on June 4, the president of BioSim, Joaquín Rodrigo, highlighted the Pharmaceutical Industry Strategy promoted by the Ministry of Health, which he defined as "a fundamental framework to order priorities, strengthen capabilities and move towards a more competitive, resilient and patient-oriented ecosystem."

Rodrigo conveyed the Association's appreciation for an initiative that "has demonstrated a clear commitment to long-term sustainability" and in whose working groups BioSim actively participates alongside other stakeholders in the sector. He also reiterated the Association's willingness to continue contributing to the development of measures that will allow for the full utilization of the potential of biosimilar medicines to improve access to biological treatments and strengthen the sustainability of the National Health System.

According to Rodrigo, “we are at a particularly relevant regulatory, political, and social juncture. The debate on the sustainability of the healthcare system, equitable access to innovation, and Europe’s strategic autonomy has taken center stage.” The president alluded to continental initiatives such as the reform of European pharmaceutical legislation, the European Biotechnology Act, and the Critical Medicines ActThe Urban Wastewater Treatment Directive (UWWTD) and the current review of public procurement rules reflect a growing institutional awareness of the need to adapt public policies to current challenges in health, security of supply, and environmental impact. The simultaneous review of numerous European and national regulatory frameworks will determine the capacity of Europe and Spain to guarantee access to medicines, strengthen their strategic autonomy, and maintain a competitive industrial base in the coming decades. Added to this are ambitious and necessary legislative projects in our country, such as the Draft Law on Medicines and the Royal Decree on Health Technology Assessment.

According to the president of BioSim, in this scenario of global transformation, “the Pharmaceutical Industry Strategy must be established as the great national lever: the strategic board from which to articulate a joint response from all agents of the sector, transforming this regulatory challenge into a real opportunity for growth and sustainability for the entire sector.”

A National Biosimilars Plan to strengthen the National Health System

It is precisely within the framework of the Joint Strategy Committee that BioSim has proposed a National Biosimilars Plan as a priority measure, whose main objective is to facilitate the rapid adoption of these drugs in the NHS through concrete goals.

The Plan responds to the national reality: despite the growing evidence that supports them as a tool for access and sustainability, their use in the National Health System remains uneven and slower than in other European countries, which limits their potential to make pharmaceutical spending more efficient and to ensure that more patients have access (and do so sooner) to biological therapies.

Rodrigo summarizes this Plan as 'the necessary strategic integration of biosimilars into the country's pharmaceutical policy under a clear premise: maximizing health outcomes at the lowest possible cost' and to achieve this, he reaffirmed BioSim's commitment to continue collaborating with the Ministry of Health, the Cortes Generales, the Autonomous Communities and all health agents with a common goal: to guarantee equitable, sustainable and efficient access to biological treatments while strengthening Spain's industrial and biotechnological capacity.